Detalles de la búsqueda
1.
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Ann Neurol
; 85(1): 125-136, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30450637
Resultados
1 -
1
de 1
1
Próxima >
>>